Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 235

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 8
Chunk 235
---
 administrative

    18,457

    22,530

    Restructuring charges

    3,343

    —

    Impairment charges

    1,469

    —

    Total operating expense

    80,738

    84,072

    Loss from operations

    (73,048
    )

    (76,196
    )

    Other income (expense), net:

    Interest income, net

    5,255

    6,999

    Other income, net

    4,675

    —

    Total other income, net

    9,930

    6,999

    Net loss

    (63,118
    )

    (69,197
    )

    Net unrealized gain on marketable securities

    60

    956

    Comprehensive loss
     
    $
    (63,058
    )
     
    $
    (68,241
    )

    Net loss per share, basic and diluted
     
    $
    (1.65
    )
     
    $
    (1.83
    )

    Weighted-average shares outstanding, basic and diluted

    38,183,931

    37,811,984

See accompanying notes to the consolidated financial statements. 

90

BOLT BIOTHERAPEUTICS, INC. 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 

(in thousands, except share amounts) 

    Additional

    Accumulated Other

    Total

    Common

    Paid-In

    Comprehensive

    Accumulated

    Stockholders'

    Shares

    Amount

    Capital

    Income (Loss)

    Deficit

    Equity

    Balance at December 31, 2022

    37,797,902

    $
    —

    $
    467,513

    $
    (919
    )
     
    $
    (295,088
    )
     
    $
    171,506

    Issuance of common stock upon vesting of restricted stock units

    58,034

    —

    —

    —

    —

    —

    Issuance of common stock under employee stock purchase plan

    254,169

    —

    247

    —

    —

    247

    Issuance of common stock upon exercise of stock options

    4,501

    —

    6